Author

Stuart H. Bloom

Observed names: Stuart Bloom, Stuart Hunegs Bloom

Institution: University of Minnesota

Observed institutions: Northwestern University, Fox Chase Cancer Center, University of Minnesota, Abbott Northwestern Hospital, Mayo Clinic, Dana-Farber Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Masonic Cancer Center, Indiana University

ORCID: 0000-0002-5776-9852

Observed ORCID: 0000-0002-5776-9852

OpenAlex ID: A5089979038

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

2022 · Nicholas J. Vogelzang, Tomasz M. Beer, et al. · JAMA Oncology · 100

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103)

2018 · Kathy D. Miller, Anne O’Neill, et al. · Journal of Clinical Oncology · 73

Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.

2014 · Kathy Miller, Anne M. O'Neill, et al. · Journal of Clinical Oncology · 63

Cholecystitis as the presenting manifestation of acute myeloid leukemia

2002 · Stuart H. Bloom, James E. Coad, et al. · American Journal of Hematology · 15

Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.

2026 · Alicia K. Morgans, Olivia Bobek, et al. · Journal of Clinical Oncology · 4

Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients

2026 · Ali T. Arafa, Ella Boytim, et al. · Cell Reports Medicine · 3

Integrated CTC- and EV-based detection of PSMA protein and efficacy of 177 Lu-PSMA-617 radioligand therapy.

2025 · Ali Arafa, Megan Ludwig, et al. · Journal of Clinical Oncology · 1

Limited Knowledge

2021 · Stuart H. Bloom · Journal of Clinical Oncology · 1

Serial proteomic characterization of plasma extracellular vesicles (EV) to identify changes that predict outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving 177 Lu-PSMA-617.

2026 · Ali Arafa, Lauren Yu, et al. · Journal of Clinical Oncology

In Defense of Futile Gestures

2008 · Stuart H. Bloom · Journal of Clinical Oncology

Caring in five minutes

2008 · Stuart H. Bloom · Community Oncology

Works count: 11

Citation count: 259

H-index: 4

I10-index: 4